GPR75 inhibitor program(AstraZeneca/Regeneron)

N/A

Report date: 2025/08/13 13:35:59
NME

Base Information

Drug NameGPR75 inhibitor program(AstraZeneca/Regeneron)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProbable G-protein coupled receptor 75 inhibitors
TargetsProbable G-protein coupled receptor 75
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca PlcRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A